Biosimilars - Global Strategic Business Report

Description: This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.

Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 71 companies including many key and niche players such as -

- Amgen Inc.
- Allergan Plc
- Biocon Ltd.
- Biopartners GmbH
- Boehringer Ingelheim GmbH

Contents:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Introduction to Biosimilars
- Biosimilars Set to Revolutionize Healthcare Sector
- Biosimilars Offer Great Promise despite Challenges
- Specific Guidelines for Biosimilars in Various Countries with Year of Publication
- List of Approved Biosimilars & Pending Biosimilar Applications in the EU
- List of Approved Biosimilars & Pending Biosimilar Applications in the US
- List of Approved Biosimilars in South Korea
- Biosimilars Find More Growth in Emerging Markets
- Comparison of Entry Barriers for Biogenerics in Select Global Markets
- Market Drivers
- Patent Expiry of Leading Biopharmaceuticals Leads Way for Biosimilars
- Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
- Cost Containment Measures

Table 1: Per-Capita Healthcare Expenditure in Select Regions: 2013 (includes corresponding Graph/Chart)
Table 2: Leading Countries with the Highest Healthcare Spending as a Percentage of GDP (2012) (includes corresponding Graph/Chart)
Table 3: Global Population Statistics for the 65+ Age Group (2013) (includes corresponding Graph/Chart)
Table 4: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)
Table 5: Percentage of Population Aged 65 and Above in EU-27 Countries, US and Japan (1960-2030) (includes corresponding Graph/Chart)
- Growing Aging Population
- Presence of Major Players
- Growth Restraints
- Uncertain Regulations
- High Lead-time
- High Manufacturing Costs
- Delivery and Commercialization
Automatic Substitution
Other Impediments to Market Acceptance
Strategies to Aid Survival of Companies

2. RECENT BIOSIMILAR APPROVALS AND PIPELINE ANALYSIS
Biosimilar Approvals in 2016, 2015, & 2014
Select Biosimilar Candidates in Late-Stage Pipeline: 2016
Biosimilars in Pipeline for Major Biologic Drugs: 2016
Increasing Collaborations, Licensing Routes and Partnerships
Indian & Chinese Companies to Emerge Strong in Western Markets
Improved Regulatory Framework
European Union Ahead in the Biosimilars Race
Biosimilars Regulatory Agencies in Select Regional Markets
US Passes Act to Create Biosimilars Pathway, Finally

3. MARKET DYNAMICS & TRENDS
Increased Penetration of Biosimilars
Implications for Manufacturers
Efforts to Push Up Biosimilar Adoption
Improvements in Nomenclature and Interchangeability
Contract Manufacturing Favorable by Emerging & Major Biosimilar Players
Companies Eye Human Insulin Biosimilars
Table 6: Global Basal Insulin Market by Brand (2016E, 2018E & 2020E): Percentage Market Share Breakdown of Revenues for Basalgar, Lantus, Levemir, Peg Lispro, Toujeo, and Tresiba (includes corresponding Graph/Chart)
Monoclonal Antibodies
A Key Growth Segment for Biosimilars
Approved Monoclonal Antibodies for Therapeutic Use: 1986-2014
Biobetters: Potential Industry Challenge?
High Cost of Biologics
Favorable for Biosimilars
Table 7: Treatment Costs by Drug (2015): Comparative Analysis of Daily Treatment costs with Branded Small-molecule Drug, Generic Small-molecule Drug, and Biologics (Humira, Kadcyla, & Cerezyme) (includes corresponding Graph/Chart)
R&D Funding Crucial
Table 8: Global Biopharmaceutical R&D Expenditure: 2010-2015E (includes corresponding Graph/Chart)
Growing Biosimilars Market
A Clear Advantage for Bioseparation Technologies

4. GLOBAL BIOLOGICS MARKET
Global Biopharmaceutical Drug Market
A Primer
Table 9: Increasing Share of Biologics in the Global Pharmaceutical Market: 2013-2020 (includes corresponding Graph/Chart)
US
The Largest Biologics Market Worldwide
Table 10: Global Biologics Market by Region: Percentage Share Breakdown for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for 2007, 2015 and 2020 (includes corresponding Graph/Chart)
Increasing Share of Biotechnological Drugs to Drive Biosimilars Market
Intensifying Consolidation Activity

5. PRODUCT OVERVIEW
Introduction
Characteristics of Biosimilars
Biological Drugs
Biological Drugs Manufacturing Process
Development Cycle of Biosimilars
Industry Participants

6. PRODUCT APPROVALS/INTRODUCTIONS
Mylan and Biocon Co-develop trastuzumab Biosimilar
EC Approves Remicade Biosimilar Flixabi® Developed by Samsung Bioepis
Samsung's BLA for Remicade Biosimilar Accepted by USFDA
EMA Approves rituximab Biosimilar Developed by Sandoz
EC Approves New Route of Administration for Sandoz’s Biosimilar Binocrit
USFDA Approves INFLECTRA, Celltrion's Biosimilar to Remicade
Japanese Ministry Approves Biocon's Biosimilar Insulin Glargine
EMA Accepts Sandoz’s MAA for Neulasta Biosimilar
FDA Accepts Amgen's BLA for ABP-501
EC Approves Benepali (Enbrel Biosimilar) Developed by Samsung Bioepis
Torrent Pharmaceuticals Launches adalimumab Biosimilar
EMA Accepts Sandoz’s MAA for Enbrel Biosimilar
RENFLEXIS® by Samsung Bioepis Approved by Korea's MFDS
Amgen Submits ABP-501 Marketing Authorization Application to EMA
FDA Approves Sandoz's BLA for Proposed Enbrel Biosimilar
Amgen and Allergan Announce Positive Phase 3 Study Results for Biosimilar ABP 215
Korean Ministry Approves BRENZYSTM Co-developed by Merck and Samsung
Intas Pharmaceuticals Launches Biosimilar to Lucentis
USFDA Approves First Biosimilar Zarxio™ from Sandoz
Mundipharma Launches Biosimilar MAb Remsima® in 6 European Markets
Intas Pharmaceuticals Launches filgrastim Biosimilar Accofil
Cadila Launches adalimumab Biosimilar
EPIRUS Biopharmaceuticals Launches infliximab Biosimilar
Celltrion Receives Japan’s MHLW Approval for Remsima
Cipla Launches Biosimilar Darbepoetin alfa Under Actorise Brand
Celltrion Announces Approval of biosimilar mAb Herzuma by MFDS

7. RECENT INDUSTRY ACTIVITY
Alvotech Acquires Baliopharm GmbH
Dr. Reddy’s Inks Collaboration Agreement with TR-Pharm
Premier and Oncobiologics Collaborate to Enhance Biosimilars Adoption
Sandoz Acquires Rights to infliximab Biosimilar from Pfizer
Sandoz Enters into Exclusive License Agreement with Kyowa Hakko Kirin
Mylan Enters Into Biosimilars Development Partnership with Momenta Pharmaceuticals
Merck to Bring Biosimilars to Canada through its Agreement with Samsung
EPIRUS Biopharmaceuticals to Expand Biosimilar Pipeline through Acquisition of Bioceros
Pfizer Acquires Hospira
Astrazeneca Enters into JV with Fujifilm Kyowa Kirin Biologics
STADA and Richter Sign License/Distribution Agreement for Pegfilgrastim Biosimilar
Coherus and Baxter Amend Collaboration Agreement for CHS-0214
Torrent Pharmaceuticals Enters into Licensing Agreement with Reliance Life Sciences
Mabion Extends Agreement with Altiora for rituximab Biosimilar MabionCD20
STADA and mAbxience Enter Into In-licensing Agreement for Humira Biosimilar
Xbrane Bioscience Signs Agreement with Indian Pharmaceutical Major
Cipla Acquires Mabpharm
EPIRUS Biopharmaceuticals Merges with Zalicus
mAbxience Acquires Genhelix
Ipca and Oncobiologics Enter into Alliance for Development of Biosimilar MAbs
Lupin and Yoshindo Form Joint Venture YLB for Biosimilar Commercialization
Bionovis and Merck Sign Agreement
Catalent Signs Agreement with HiSUN
Aurobindo Pharma Acquires Western European Operations of Actavis
Samsung and Merck Expand Collaboration to Develop MK-1293 Insulin Glargine Biosimilar

8. FOCUS ON SELECT MARKET PLAYERS
Amgen Inc. (US)
Allergan Plc. (Ireland)
Biopartners GmbH (Switzerland)
Boehringer Ingelheim GmbH (Germany)
Celltrion Inc. (South Korea)
Cipla Ltd. (India)
Cipla BioTec Private Ltd. (India)
Dr. Reddy's Laboratories Ltd. (India)
Eli Lilly and Company (US)
EPIRUS Biopharmaceuticals, Inc. (US)
Hospira, Inc. (US)
Intas Biopharmaceuticals Ltd. (India)
Merck KGaA (Germany)
Mylan N.V. (US)
Pfizer Inc. (US)
Samsung Bioepis Co., Ltd. (Korea)
Sandoz International GmbH (Germany)
STADA Arzneimittel AG (Germany)
Teva Pharmaceutical Industries Ltd. (Israel)

9. GLOBAL MARKET PERSPECTIVE
Table 11: World Recent Past, Current, and Future Analysis for Biosimilars by Geographic Region
US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 12: World 7-Year Perspective for Biosimilars by Geographic Region
Percentage Breakdown of Dollar Revenues for US, Japan, Europe and Rest of World Markets for Years 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A. Market Analysis
   Market Overview
   Latest Developments in the Biosimilars Space
   Slow Take-Off in the US Market
   List of Approved Biosimilars & Pending Biosimilar Applications in the US
   Challenges in the US Drug Approval Pathway for Biosimilars
   Growing Legal Challenges in the Domestic Market
   Need to Cut Down Prices for Increased Adoption
   Patent Expiry of Leading Biopharmaceuticals Presents Ray of Hope
   Patent Expiries of Major Biopharmaceutical Drugs in the US
   Significant Biosimilar Pipeline Products
   Product Introductions
   Strategic Corporate Developments
   Select Key Players
B. Market Analytics
   Table 13: The US Recent Past, Current & Future Analysis for Biosimilars Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

2. JAPAN
A. Market Analysis
   Growing Market for Biosimilars
   Product Introductions
   Strategic Corporate Developments
B. Market Analytics
   Table 14: Japanese Recent Past, Current & Future Analysis for Biosimilars Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

3. EUROPE
A. Market Analysis
   List of Approved Biosimilars & Pending Biosimilar Applications in the EU
   Patent Expiry of Leading Biopharmaceuticals Leads Way for Biosimilars
   Patent Expiries of Major Biopharmaceutical Drugs in Europe
   Biosimilar Pricing Competition to Intensify Further
   Clarity Needed Regarding Extrapolation of Biosimilars for Other Indications
   Demand for Rituximab Biosimilars
   Nascent UK Biosimilars Market
   NICE’s Latest Ruling Bodes Well for Biosimilars
   Spanish Biosimilars Market: A Brief Review
   Biosimilar-related Developments in Russia
   Biosimilars Regulatory Framework: Well-Established
   Biosimilar Regulatory Timeline from Legislation to Approval in the EU
Growth Drivers
Payers Eye Biosimilars to Curtail Costs
Challenges Ahead
Heavy Investment and Regulations
Complex Production Process
Biocapacity
Product Introductions
Strategic Corporate Developments
Select Key Players

B. Market Analytics
Table 15: European Recent Past, Current & Future Analysis for Biosimilars by Geographic Region
France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 16: European 7-Year Perspective for Biosimilars by Geographic Region
Percentage Breakdown of Dollar Revenues for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2016 & 2022 (includes corresponding Graph/Chart)

3a. FRANCE
Market Analysis
Table 17: French Recent Past, Current & Future Analysis for Biosimilars Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

3b. GERMANY
Market Analysis
Table 18: German Recent Past, Current & Future Analysis for Biosimilars Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

3c. ITALY
Market Analysis
Table 19: Italian Recent Past, Current & Future Analysis for Biosimilars Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

3d. UNITED KINGDOM
Market Analysis
Table 20: The UK Recent Past, Current & Future Analysis for Biosimilars Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

3e. SPAIN
Market Analysis
Table 21: Spanish Recent Past, Current & Future Analysis for Biosimilars Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

3f. REST OF EUROPE
Market Analysis
Table 22: Rest of European Recent Past, Current & Future Analysis for Biosimilars Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

4. REST OF WORLD
A. Market Analysis
Asia-Pacific: Market with High Potential
Regulatory Framework
Asia-Pacific
List of Approved Biosimilars in South Korea
Latin America
Middle East and North Africa
Sub-Saharan Africa
High Costs and Counteractive Measures
Indian Biopharmaceutical Industry Makes Rapid Progress
Competition from Western Counterparts in Biosimilar Development
China Issues New Guidelines on Biosimilars
Overview of Biosimilars in Sub-Saharan Africa
Canada
Biosimilars Set to Register Gains in Pharmaceutical Sector
Future Scenario
Regulatory Framework
Product Introductions
Strategic Corporate Developments
Select Key Players
B. Market Analytics

Table 23: Rest of World Recent Past, Current & Future Analysis for Biosimilars Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 71 (including Divisions/Subsidiaries 77)
The United States (15)
Canada (1)
Japan (3)
Europe (25)
- France (1)
- Germany (8)
- The United Kingdom (5)
- Spain (1)
- Rest of Europe (10)
Asia-Pacific (Excluding Japan) (30)
Latin America (1)
Middle-East (2)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1227769/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Biosimilars - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/1227769/
Office Code: SCH377U3

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 4500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td>USD 6300</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users</td>
<td>USD 8550</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 15 Users</td>
<td>USD 10800</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ____________________________  Last Name: ____________________________
Email Address: * ____________________________
Job Title: ____________________________
Organisation: ____________________________
Address: ____________________________
City: ____________________________
Postal / Zip Code: ____________________________
Country: ____________________________
Phone Number: ____________________________
Fax Number: ____________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: __________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA

+353-1-481-1716 or +353-1-653-1571 - From Rest of World